Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
Phase 2 study of lifileucel TIL therapy in 220 patients with metastatic melanoma
Can a patient's own immune cells be turned into a treatment for advanced melanoma?
A prospective, multicenter, phase 2 interventional study evaluated lifileucel (autologous tumor-infiltrating lymphocytes, LN-144) infusion a…
A new treatment uses a patient's own immune cells to fight advanced melanoma, but results from the mid-stage trial are not yet available.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
Phase 3 Study Evaluates Barzolvolimab for Chronic Spontaneous Urticaria
Can a new treatment finally help those suffering from chronic hives?
A Phase 3 trial assesses barzolvolimab's efficacy and safety in CSU patients unresponsive to antihistamines.
Adults with chronic hives who don't get relief from standard antihistamines may find new hope in a new treatment called barzolvolimab being …
Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks
Could Sliding Cupping Therapy Be a Game-Changer for Psoriasis Patients?
In a RCT with 60 psoriasis patients, sliding cupping showed similar efficacy to NBUVB in reducing PASI scores by 62.4% vs. 66.9% (P=.526).
Sliding cupping therapy improved psoriasis symptoms just as well as standard light treatment, offering a viable alternative for patients see…